Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
A Phase Ib/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer
Sponsor: Pfizer
Listed as NCT01719380, this PHASE2 trial focuses on Colorectal Cancer and remains completed. Sponsored by Pfizer, it has been updated 14 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE2
▶ Show 9 earlier versions
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE2
Phase: PHASE1_PHASE2 → PHASE2
-
Aug 2020 — Dec 2020 [monthly]
Completed PHASE1_PHASE2
-
May 2019 — Aug 2020 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Oct 2018 — May 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Mar 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Feb 2017 — Mar 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Nov 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amsterdam, Netherlands , Barcelona, Spain , Boston, United States , Chuo-ku, Japan , Cologne, Germany , Dickson, United States , Essen, Germany , Franklin, United States , Gallatin, United States , Gangnam-Gu, South Korea and 27 more locations